inclusion criteria: - critically ill patients infected with covid-19 (clinical/confirmed) - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or or - spo2 ≤94% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

inclusion criteria: - critically ill patients infected with covid-19 (clinical/confirmed) - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or or - spo2 ≤94% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

inclusion criteria: - critically ill covid-19 patients who have been tested positive by rt-pcr for sars-cov-2 on the nasopharyngeal or throat swabs - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - spo2 ≤90% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

inclusion criteria: - critically ill covid-19 patients who have been tested positive by rt-pcr for sars-cov-2 on the nasopharyngeal or throat swabs - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - spo2 ≤90% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

inclusion criteria: - critically ill patients infected with covid-19 (clinical/confirmed) - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 ≤94% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

inclusion criteria: - critically ill patients infected with covid-19 (clinical/confirmed) - patient aged 18 years or more of either gender - illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 ≤94% on room air, or - requiring mechanical ventilation and/or supplemental oxygen - female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.